Abstract
Suicide risk is a major cause of death among patients with schizophrenia. Death by suicide has been reported in approximately 5% of schizophrenia patients although this figure appears to be an underestimate of the problem. A number of risk factors are routinely reported as associated with suicide risk among these patients, some of which are modifiable by targeted therapeutic strategies. Clozapine is the only compound that gathered evidence as an effective treatment for reducing suicide risk in schizophrenia. Long-Acting Injectable Antipsychotics (LAIs) have a range of advantages in terms of efficacy, safety and tolerability in the treatment of schizophrenia, and one area of interest is whether LAI-treatment may decrease suicidality by indirectly acting on a range of risk factors for suicide specific to schizophrenia patients. This background encouraged the present review of research pertaining to LAIs in relation to modifiable risk factors for suicide in schizophrenia. We viewed our task as gathering, speculating and critically appraising the available research relevant to the topic, with the aim of formulating a hypothesis to be tested with further research.
Keywords: Long-acting injectable antipsychotics, prevention, schizophrenia, suicide, pharmacological, hallucination.
CNS & Neurological Disorders - Drug Targets
Title:Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?
Volume: 16 Issue: 4
Author(s): Maurizio Pompili*, Laura Orsolini, Dorian A. Lamis, David R. Goldsmith, Adele Nardella, Giulia Falcone, Valentina Corigliano, Mario Luciano and Andrea Fiorillo
Affiliation:
- Department of Psychiatry, Sant’Andrea Hospital, Sapienza University of Rome, Via di Grottarossa 1035, 00189 Rome,Italy
Keywords: Long-acting injectable antipsychotics, prevention, schizophrenia, suicide, pharmacological, hallucination.
Abstract: Suicide risk is a major cause of death among patients with schizophrenia. Death by suicide has been reported in approximately 5% of schizophrenia patients although this figure appears to be an underestimate of the problem. A number of risk factors are routinely reported as associated with suicide risk among these patients, some of which are modifiable by targeted therapeutic strategies. Clozapine is the only compound that gathered evidence as an effective treatment for reducing suicide risk in schizophrenia. Long-Acting Injectable Antipsychotics (LAIs) have a range of advantages in terms of efficacy, safety and tolerability in the treatment of schizophrenia, and one area of interest is whether LAI-treatment may decrease suicidality by indirectly acting on a range of risk factors for suicide specific to schizophrenia patients. This background encouraged the present review of research pertaining to LAIs in relation to modifiable risk factors for suicide in schizophrenia. We viewed our task as gathering, speculating and critically appraising the available research relevant to the topic, with the aim of formulating a hypothesis to be tested with further research.
Export Options
About this article
Cite this article as:
Pompili Maurizio*, Orsolini Laura, Lamis A. Dorian, Goldsmith R. David, Nardella Adele, Falcone Giulia, Corigliano Valentina, Luciano Mario and Fiorillo Andrea, Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170223163629
DOI https://dx.doi.org/10.2174/1871527316666170223163629 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors
Current Drug Targets Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Zolpidem Therapy for Movement Disorders
Recent Patents on CNS Drug Discovery (Discontinued) 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Antipsychotics and Cognitive Functioning: A Critical Review
Current Psychopharmacology Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science 3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Emerging Biology of PDE10A
Current Pharmaceutical Design Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology